Mackenzie Financial Corp bought a new stake in Intersect ENT Inc (NASDAQ:XENT) during the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm bought 42,160 shares of the medical equipment provider’s stock, valued at approximately $1,313,000. Mackenzie Financial Corp owned about 0.14% of Intersect ENT as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also added to or reduced their stakes in XENT. Teachers Advisors LLC grew its holdings in Intersect ENT by 3.5% in the 1st quarter. Teachers Advisors LLC now owns 61,858 shares of the medical equipment provider’s stock valued at $1,061,000 after buying an additional 2,084 shares during the last quarter. Vanguard Group Inc. grew its holdings in Intersect ENT by 7.4% in the 1st quarter. Vanguard Group Inc. now owns 1,067,873 shares of the medical equipment provider’s stock valued at $18,314,000 after buying an additional 73,615 shares during the last quarter. Geode Capital Management LLC grew its holdings in Intersect ENT by 3.7% in the 1st quarter. Geode Capital Management LLC now owns 234,881 shares of the medical equipment provider’s stock valued at $4,028,000 after buying an additional 8,417 shares during the last quarter. Schwab Charles Investment Management Inc. grew its holdings in Intersect ENT by 6.1% in the 1st quarter. Schwab Charles Investment Management Inc. now owns 120,838 shares of the medical equipment provider’s stock valued at $2,073,000 after buying an additional 6,963 shares during the last quarter. Finally, Bank of America Corp DE grew its holdings in Intersect ENT by 3.9% in the 1st quarter. Bank of America Corp DE now owns 103,275 shares of the medical equipment provider’s stock valued at $1,771,000 after buying an additional 3,892 shares during the last quarter. 86.31% of the stock is currently owned by hedge funds and other institutional investors.

A number of brokerages have commented on XENT. Bank of America raised their price objective on Intersect ENT from $33.00 to $40.00 and gave the stock a “buy” rating in a research report on Monday, September 11th. Canaccord Genuity raised their price objective on Intersect ENT from $32.00 to $37.00 and gave the stock a “buy” rating in a research report on Wednesday, September 13th. Zacks Investment Research upgraded Intersect ENT from a “hold” rating to a “buy” rating and set a $33.00 price objective for the company in a research report on Thursday, October 5th. Piper Jaffray Companies reiterated a “buy” rating and issued a $35.00 price objective on shares of Intersect ENT in a research report on Tuesday, August 22nd. Finally, BidaskClub downgraded Intersect ENT from a “buy” rating to a “hold” rating in a research report on Wednesday, December 6th. Five equities research analysts have rated the stock with a hold rating and six have given a buy rating to the company’s stock. The company currently has a consensus rating of “Buy” and a consensus price target of $32.43.

In related news, COO Richard E. Kaufman sold 13,639 shares of the firm’s stock in a transaction on Monday, September 25th. The stock was sold at an average price of $28.97, for a total transaction of $395,121.83. Following the completion of the sale, the chief operating officer now directly owns 133,757 shares of the company’s stock, valued at approximately $3,874,940.29. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Lisa D. Earnhardt sold 20,000 shares of the firm’s stock in a transaction on Friday, September 15th. The shares were sold at an average price of $30.19, for a total value of $603,800.00. Following the sale, the insider now directly owns 525,868 shares of the company’s stock, valued at $15,875,954.92. The disclosure for this sale can be found here. Insiders have sold a total of 113,838 shares of company stock valued at $3,317,410 over the last ninety days. Insiders own 13.70% of the company’s stock.

Intersect ENT Inc (NASDAQ:XENT) opened at $28.60 on Monday. Intersect ENT Inc has a 52-week low of $10.82 and a 52-week high of $33.25.

Intersect ENT (NASDAQ:XENT) last released its quarterly earnings results on Thursday, November 2nd. The medical equipment provider reported ($0.15) earnings per share for the quarter, beating the Zacks’ consensus estimate of ($0.20) by $0.05. Intersect ENT had a negative return on equity of 15.96% and a negative net margin of 19.81%. The firm had revenue of $22.31 million during the quarter, compared to analysts’ expectations of $21.53 million. During the same period last year, the firm posted ($0.22) EPS. The business’s revenue was up 20.8% on a year-over-year basis. equities analysts predict that Intersect ENT Inc will post -0.63 EPS for the current year.

COPYRIGHT VIOLATION WARNING: “Mackenzie Financial Corp Invests $1.31 Million in Intersect ENT Inc (XENT)” was originally posted by Daily Political and is the sole property of of Daily Political. If you are accessing this story on another publication, it was illegally copied and republished in violation of U.S. & international trademark and copyright legislation. The correct version of this story can be viewed at https://www.dailypolitical.com/2017/12/11/mackenzie-financial-corp-invests-1-31-million-in-intersect-ent-inc-xent.html.

Intersect ENT Company Profile

Intersect ENT, Inc is a commercial-stage drug-device company. The Company develops drugs for patients with ear, nose and throat (ENT) conditions. The Company has developed a drug releasing bioabsorbable implant technology that enables targeted and sustained release of therapeutic agents. This targeted drug delivery technology is designed to allow ENT physicians to manage patient care.

Want to see what other hedge funds are holding XENT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Intersect ENT Inc (NASDAQ:XENT).

Institutional Ownership by Quarter for Intersect ENT (NASDAQ:XENT)

Receive News & Ratings for Intersect ENT Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intersect ENT Inc and related companies with MarketBeat.com's FREE daily email newsletter.